FDA slaps CRL on Seikagaku’s BLA for condoliase

14 March 2025

Japanese drugmaker Seikagaku Corporation (TYO: 4548) announced that it has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) concerning Seikagaku’s biologics license application (BLA) for SI-6603 (condoliase), a treatment that reduces leg pain associated with lumbar disc herniation.

The company noted that no concerns about the clinical study results, including the efficacy and safety of SI-6603, were expressed by the FDA, and no additional clinical studies are required. However, additional observations were made, mainly concerning the manufacturing facility, control of drug substance and drug product.

Seikagaku will now work closely with the FDA and Switzerland-based Ferring Pharmaceuticals, which concluded a global (excluding Japan) license agreement for SI-6603 with Seikagaku in 2016, and consider a prompt resubmission in preparation for regulatory approval.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology